Active, not recruitingPHASE1, PHASE2NCT04902872
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Studying Epithelial tumor of the appendix
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cybrexa Therapeutics
- Intervention
- CBX-12(drug)
- Enrollment
- 130 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (4)
- Yale Cancer Center, New Haven, Connecticut, United States
- NEXT Oncology, Austin, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- NEXT Oncology, San Antonio, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04902872 on ClinicalTrials.govOther trials for Epithelial tumor of the appendix
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06513065Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)University of Southampton
- RECRUITINGPHASE2NCT06800391Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei PatientsFondazione IRCCS Istituto Nazionale dei Tumori, Milano
- RECRUITINGNCT05734430Genetics of Appendix Cancer StudyAndreana Holowatyj, PhD, MSCI
- ACTIVE NOT RECRUITINGNANCT05623787Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal NeoplasmsLaval University
- RECRUITINGNANCT04024917Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal CarcinosisInstitut du Cancer de Montpellier - Val d'Aurelle
- ACTIVE NOT RECRUITINGPHASE2NCT03074513Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT02387203Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal OriginMercy Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT01815359ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal MetastasisMemorial Sloan Kettering Cancer Center